Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St

March 01, 2025

Fulgent Genetics (NASDAQ:FLGT) Full Year 2024 Results

Key Financial Results

Revenue: US$283.5m (down 2.0% from FY 2023).
Net loss: US$42.7m (loss narrowed by 75% from FY 2023).
US$1.41 loss per share (improved from US$5.64 loss in FY 2023).

earnings-and-revenue-growth — NasdaqGM:FLGT Earnings and Revenue Growth March 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fulgent Genetics EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 6.1% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for Fulgent Genetics you should be aware of.

If you're looking to trade Fulgent Genetics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.